Roche Holding AG Bearer Shares RO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Roche Targets Emerging Oncology Market With New Lung-Cancer Drug
-
Genentech’s Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer
-
Genentech Presents Interim Phase III Data Showing Sefaxersen Significantly Reduced Proteinuria in People With IgA Nephropathy (IgAN)
-
Zymeworks, Roche Enter Collaboration to Develop Experimental Lung Cancer Drug
-
Roche CEO Signals New Wave of Drugs to Fuel Growth Next Year, Beyond — Update
-
Roche Posts Higher Sales on Growth Across Pharma, Diagnostics Units
-
Genentech Presents New Pivotal Trial Data Across Broad Neuroimmunology Portfolio at MSToronto2026
-
Roche Partners With China's Hansoh in Deal That Could Top $15 Billion — Update
Trading Information
- Previous Close Price
- CHF 405.40
- Day Range
- CHF 400.00–406.20
- 52-Week Range
- CHF 270.80–406.20
- Bid/Ask
- CHF 401.00 / CHF 401.40
- Shares Outstanding
- 796.77M
- Market Cap
- CHF 319.50B
- Volume/Avg
- 4,285 / 28,093
Key Statistics
- Price/Earnings (Normalized)
- 22.07
- Price/Sales
- 5.18
- Dividend Yield (Trailing)
- 2.42%
- Dividend Yield (Forward)
- 2.42%
- Dividend Payment Schedule
- Mar
- Total Yield
- 2.42%
Company Profile
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Core
- Total Number of Employees
- 112,774
- Website
- https://www.roche.com
Competitors
Valuation
|
Metric
|
RO
|
MRK
|
ABBV
|
|---|---|---|---|
Price/Earnings (Normalized) | 22.07 | 44.18 | 26.35 |
Price/Book Value | 9.88 | 8.35 | — |
Price/Sales | 5.18 | 5.29 | 7.89 |
Price/Cash Flow | 16.23 | 15.88 | 21.73 |
Price/Earnings
RO
MRK
ABBV
Financial Strength
|
Metric
|
RO
|
MRK
|
ABBV
|
|---|---|---|---|
Quick Ratio | 0.80 | 0.71 | 0.49 |
Current Ratio | 1.23 | 1.32 | 0.81 |
Interest Coverage | 13.49 | 4.28 | 3.89 |
Quick Ratio
RO
MRK
ABBV
Profitability
|
Metric
|
RO
|
MRK
|
ABBV
|
|---|---|---|---|
Return on Assets (Normalized) | 15.81% | 6.27% | 14.29% |
Return on Equity (Normalized) | 48.77% | 16.68% | — |
Return on Invested Capital (Normalized) | 23.90% | 9.82% | 32.02% |
Return on Assets
RO
MRK
ABBV
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|Ly@R!D% | LOCK|fvH | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|R$hRJF | LOCK|%W | $647B | |||
| AbbVie Inc
ABBV
| LOCK|^XMm&V | LOCK|yP | $506B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|VP#Z!%#> | LOCK|gy | $385B | |||
| Merck & Co Inc
MRK
| LOCK|Q#$rsq | LOCK|$N | $350B | |||
| Novartis AG ADR
NVS
| LOCK|#J>Sg!$x | LOCK|h<F | $294B | |||
| AstraZeneca PLC
AZN
| LOCK|$R%BmdbY | LOCK|Zb% | $265B | |||
| Amgen Inc
AMGN
| LOCK|C?@?tC> | LOCK|Gq | $242B | |||
| Gilead Sciences Inc
GILD
| LOCK|Q%&HMb | LOCK|#q& | $197B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|p%F#gPv | LOCK|%Y | $171B |
United States